The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 3:35 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #60. Acorda Therapeutics, Inc. Two neuropathic pain management assets from NeurogesX, Inc.

Acquirer: Acorda Therapeutics, Inc. (ACOR)
Acquiree: Two neuropathic pain management assets from NeurogesX, Inc. (NGSX)
Details: Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. (OTCBB:NGSX). Qutenza is approved by the U.S. Food and Drug Administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia. The Company also acquired NP-1998, a Phase 3 ready, prescription strength capsaicin topical solution, being assessed for the treatment of neuropathic pain. NP-1998 was previously referred to as NGX-1998.

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as needed use and utilizes Co.'s ARCUS pulmonary delivery system. Co. also markets branded Ampyra (dalfampridine), extended release tablets, 10 mg for improving walking in people with multiple sclerosis.

Open the ACOR Page at The Online Investor »

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as needed use and utilizes Co.'s ARCUS pulmonary delivery system. Co. also markets branded Ampyra (dalfampridine), extended release tablets, 10 mg for improving walking in people with multiple sclerosis.

Open the NGSX Page at The Online Investor »

Company Name: 
Acorda Therapeutics Inc
Website: 
www.acorda.com
Sector: 
Biotechnology
Number of ETFs Holding ACOR: 
6
Total Market Value Held by ETFs: 
$1.40M
Total Market Capitalization: 
$37.00M
% of Market Cap. Held by ETFs: 
3.79%
Company Name: 
NeurogesX Inc
Website: 
www.neurogesx.com
Sector: 
Biotechnology
 

Quotes delayed 20 minutes


Biotechnology M&A - Slide 60 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.